Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008

Belgin Unal1*, Kaan Sözmen1, Hale Arık2, Gül Gerçekkilioğlu1, Deniz Utku Altun1, Hatice Şimşek1, Sinem Doganay1, Yücel Demiral1, Özgür Aslan3, Kathleen Bennett4, Martin O’Flaherty5, Simon Capewell5 and Julia Critchley6

Abstract

Background: Coronary heart disease (CHD) mortality rates have been decreasing in Turkey since the early 1990s. Our study aimed to determine how much of the CHD mortality decrease in Turkey between 1995 and 2008 could be attributed to temporal trends in major risk factors and how much to advances in medical and surgical treatments.

Methods: The validated IMPACT CHD mortality model was used to combine and analyse data on uptake and effectiveness of CHD treatments and risk factor trends in Turkey in adults aged 35–84 years between 1995 and 2008.

Data sources were identified, searched and appraised on population, mortality and major CHD risk factors for adults those aged 35–84 years. Official statistics, electronic databases, national registers, surveys and published trials were screened from 1995 onwards.

Results: Between 1995 and 2008, coronary heart disease mortality rates in Turkey decreased by 34% in men and 28% in women 35 years and over. This resulted in 35,720 fewer deaths in 2008. Approximately 47% of this mortality decrease was attributed to treatments in individuals (including approximately 16% to secondary prevention, 3% angina treatments, 9% to heart failure treatments, 5% to initial treatments of acute myocardial infarction, and 5% to hypertension treatments) and approximately 42% was attributable to population risk factor reductions (notably blood pressure 29%; smoking 27%; and cholesterol 1%). Adverse trends were seen for obesity and diabetes (potentially increasing mortality by approximately 11% and 14% respectively). The model explained almost 90% of the mortality fall.

Conclusion: Reduction in major cardiovascular risk factors explained approximately 42% and improvements in medical and surgical treatments explained some 47% of the CHD mortality fall. These findings emphasize the complimentary value of primary prevention and evidence-based medical treatments in controlling coronary heart disease.

Keywords: Coronary heart disease, Coronary heart disease mortality, Coronary heart disease risk factors, Coronary heart disease management, Turkey, Modelling

Background

Turkey has a relatively young population compared to many western societies. The total population was 75 million in 2008 and 30% were younger than 15 years of age [1]. However, population structure is changing rapidly and Turkey has almost completed its demographic transition [2]. The median age of the population thus increased from 22 years in 1990 to 27 years by 2008. The proportion of those over 65 years of age was approximately 4% in 1990 and reached to 7% in 2008 [2]. The ageing population and changes in lifestyle have contributed to increases in the burden of non-communicable diseases (NCDs) [3].

Coronary heart disease (CHD) is the major cause of death and disability in Turkey. In the Turkish National Burden of Disease Study (2000) CHD and cerebrovascular
diseases were estimated to account for 36% of all deaths [3]. In most industrialized countries, CHD mortality rates have decreased considerably since the 1970s [4]. Decreases started some 10–15 years later in middle income countries [4]. Thus in a recent analysis of CHD mortality rates in Turkey, increasing trends were observed from 1988 (366 per 100000) to 1994 (411 per 100000) but then decreasing from 1995 to reach (348 per 100000 in 2008) [5]. However, the underlying factors associated with this significant decrease in CHD mortality have not been comprehensively evaluated.

Previous studies in some high income countries have shown that improvements in major cardiovascular risk factors, including total cholesterol, blood pressure levels and smoking, explain a greater proportion of the mortality decline than treatments, ranging from 44% in the USA to 72% in Finland [6-8]. This principally reflects improvements in smoking and modifiable dietary risk factors [6-8]. However few such studies have been performed in middle or low income countries.

The information on CHD prevalence, incidence and determinants of CHD in Turkey is rapidly improving. There are several ongoing studies from the Turkish Cardiology Association [9], the Turkish Society of Hypertension and Renal Disease [10,11], the Turkish Endocrinology Association (TURDEP) [12,13] and from the Universities [14-17]. These together provide increasing good trend data on cardiovascular risk factors.

Thus, in Turkey, recent population studies document significant decreases in population blood pressure, cholesterol [18,19] and smoking prevalence [20]. However, obesity and diabetes prevalence are now increasing steeply [13,21,22] as in most other developed and developing countries.

Approximately 25%-55% of the recent CHD mortality declines in developed countries have been attributed to the use of evidence-based medical and interventional therapies [7,8,23,24]. These include aspirin, beta-blockers, ACE-inhibitors and angiotensin-receptor-blockers (ARBs), statins, fibrinolysis, percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) [7,25]. In Turkey, treatment uptake in CHD patients has increased substantially since the 1990s [26,27].

Our objective was therefore to study recent trends in CHD deaths between 1995 and 2008, using a previously validated epidemiological model, to determine the contribution of prevention and treatment strategies.

Methods
We used an updated version of the IMPACT CHD mortality model that was originally developed in Scotland and then validated in many countries including England, New Zealand, United States, Canada, Europe and China [7,24,28-30]. Data on risk factor levels and current uptake levels of evidence based medical and surgical treatments were identified by extensive search of published and unpublished data and complemented with specifically designed surveys. All data sources were critically appraised by the research team and the results are presented in Additional file 1: Table S1.

The IMPACT model was populated with data for men and women aged 35–84 (in 10 year age groups) for both 1995 and 2008. The main data items included data on: a) population sizes in each year, by age group and gender; b) Patient numbers in specific CHD groups (Myocardial Infarction, Congestive Heart Failure, Chronic Angina Pectoris, c) uptake levels of specific medical and surgical treatments, (Table 1), and d) population trends in major cardiovascular risk factors (smoking, total cholesterol, systolic blood pressure, body mass index, diabetes, physical inactivity and fruit and vegetable consumption) (Table 2). The number of CHD deaths attributable to each specific treatment and risk factor were calculated for 1995 and for 2008. The difference between the two values then represented the deaths prevented or postponed (DPP) attributed to the change in risk factors and treatment uptake levels in the population.

Information on population and demographic changes were obtained from the census (1995) and Address Based Population Registration System (2008) of the Turkish Statistical Institute [1]. Although the data collection method changed from 1995 to 2008, population projections based on the census are very close to the population of address based registration in 2008 [31].

The numbers of CHD deaths were estimated using mortality statistics from the Turkish statistical institute

Data on cause of death was collected only from urban settings which comprised approximately 50%-68% of the total population over the years 1988–2008 [1]. Therefore, the total number of deaths was estimated by inflating the urban deaths proportional to the rural population simply assuming that a similar mortality pattern existed in rural areas [3]. The total number of deaths was also inflated by 12% in men and 16% in women to account for underreporting of the deaths based on expert opinion [3]. The numbers of CHD deaths by age and sex groups for 1995 and 2008 were obtained from the Turkish Statistical Institute coded according to International Classification of Diseases, 8th Revision (corresponds to ICD9 codes 410–414) based on final cause of death [1]. Coding inaccuracy is an important limitation of the mortality data in Turkey [32]. Ill defined codes and the “other heart diseases” codes accounted for approximately 30 to 40% of the total deaths during the study period [32]. Therefore, 50% of the “other heart disease” group were allocated to CHD deaths through the study period [3].
Table 1 Estimated deaths prevented or postponed by medical or surgical treatments in Turkey in 2008

| Treatments                        | Number of eligible patients | Patients receiving treatment (%) | Relative risk reduction (%) | Mean case-fatality (%) | Absolute risk reduction | Best estimate | Minimum estimate | Maximum estimate | Best estimate | Minimum estimate | Maximum estimate |
|-----------------------------------|-----------------------------|----------------------------------|----------------------------|------------------------|-------------------------|---------------|------------------|------------------|---------------|------------------|------------------|
| Acute MI                          | 91317                       | 0.067                            |                            |                        |                         | 1677          | 684              | 3309             | 4.7           | 1.9              | 9.3              |
| Community CPR                     | 9132                        | 100                              | 0.05                       | 0.067                  | 0.055                   | 443           | 283              | 638              | 1.2           | 0.8              | 1.8              |
| Hospital CPR                      | 2740                        | 6                                | 0.32                       | 0.067                  | 0.323                   | 53            | 34               | 91               | 0.1           | 0.1              | 0.3              |
| Thrombolysis                      | 91317                       | 29                               | 0.26                       | 0.067                  | 0.014                   | 316           | 130              | 656              | 0.9           | 0.4              | 1.8              |
| Aspirin                           | 91317                       | 93                               | 0.15                       | 0.067                  | 0.010                   | 774           | 317              | 1420             | 2.2           | 0.9              | 4.0              |
| Beta blocker                      | 91317                       | 70                               | 0.04                       | 0.067                  | 0.003                   | 143           | 59               | 296              | 0.4           | 0.2              | 0.8              |
| ACE inhibitor                     | 91317                       | 61                               | 0.07                       | 0.067                  | 0.005                   | 228           | 93               | 466              | 0.6           | 0.3              | 1.3              |
| Primary PTCA                      | 91317                       | 18                               | 0.32                       | 0.067                  | 0.020                   | 589           | 241              | 1221             | 1.6           | 0.7              | 3.4              |
| Primary CABG                      | 91317                       | 9                                | 0.20                       | 0.067                  | 0.013                   | 112           | 40               | 231              |               |                  |                  |

Unstable angina

| Treatments                        | Number of eligible patients | Patients receiving treatment (%) | Relative risk reduction (%) | Mean case-fatality (%) | Absolute risk reduction | Best estimate | Minimum estimate | Maximum estimate |
|-----------------------------------|-----------------------------|----------------------------------|----------------------------|------------------------|-------------------------|---------------|------------------|------------------|
| Aspirin & heparin                 | 45658                       | 50                               | 0.33                       | 0.053                  | 0.017                   | 316           | 129              | 655              | 0.9           | 0.4              | 1.8              |
| Aspirin alone                     | 45658                       | 88                               | 0.15                       | 0.053                  | 0.008                   | 245           | 100              | 465              | 0.7           | 0.3              | 1.3              |
| PG IB/IIIA                       | 45658                       | 41                               | 0.09                       | 0.053                  | 0.005                   | 70            | 28               | 144              | 0.2           | 0.1              | 0.4              |
| CAGB surgery for UA              | 45658                       | 13                               | 0.43                       | 0.053                  | 0.023                   | 107           | 44               | 221              | 0.3           | 0.1              | 0.6              |
| PTCA for UA                      | 45658                       | 26                               | 0.32                       | 0.053                  | 0.016                   | 152           | 62               | 314              | 0.4           | 0.2              | 0.9              |

Secondary Prev Post AMI

| Treatments                        | Number of eligible patients | Patients receiving treatment (%) | Relative risk reduction (%) | Mean case-fatality (%) | Absolute risk reduction | Best estimate | Minimum estimate | Maximum estimate |
|-----------------------------------|-----------------------------|----------------------------------|----------------------------|------------------------|-------------------------|---------------|------------------|------------------|
| Aspirin                           | 759071                      | 73                               | 0.778                      | 0.045                  | 0.007                   | 2170          | 711              | 3665             | 6.1           | 2.0              | 10.3             |
| Beta blocker                      | 759071                      | 63                               | 0.526                      | 0.045                  | 0.010                   | 2052          | 672              | 3713             | 5.7           | 1.9              | 10.4             |
| ACE inhibitor                     | 759071                      | 61                               | 0.514                      | 0.045                  | 0.009                   | 1771          | 580              | 3198             | 5.0           | 1.6              | 9.0              |
| Statin                            | 759071                      | 3                                | 0.757                      | 0.045                  | 0.010                   | 1339          | 351              | 2767             | 3.7           | 1.0              | 7.7              |
| Warfarin                          | 759071                      | 8                                | 0.032                      | 0.045                  | 0.010                   | 76            | 25               | 138              | 0.2           | 0.1              | 0.4              |

Secondary Prev Post CABG/PCI

| Treatments                        | Number of eligible patients | Patients receiving treatment (%) | Relative risk reduction (%) | Mean case-fatality (%) | Absolute risk reduction | Best estimate | Minimum estimate | Maximum estimate |
|-----------------------------------|-----------------------------|----------------------------------|----------------------------|------------------------|-------------------------|---------------|------------------|------------------|
| Aspirin                           | 275652                      | 97                               | 0.15                       | 0.017                  | 0.003                   | 496           | 162              | 1076             | 1.4           | 0.5              | 3.0              |
| Beta blocker                      | 275652                      | 60                               | 0.23                       | 0.017                  | 0.004                   | 470           | 154              | 1167             | 1.3           | 0.4              | 3.3              |
| ACE inhibitor                     | 275652                      | 54                               | 0.20                       | 0.017                  | 0.003                   | 366           | 120              | 909              | 1.0           | 0.3              | 2.5              |
| Statin                            | 275652                      | 87                               | 0.22                       | 0.017                  | 0.004                   | 377           | 124              | 898              | 1.1           | 0.3              | 2.5              |
| Warfarin                          | 275652                      | 22                               | 0.22                       | 0.017                  | 0.004                   | 18            | 6                | 44               | 0.1           | 0.0              | 0.1              |
| Rehabilitation                    | 273379                      |                                  |                            |                        |                         | 83            | 27               | 208              | 0.2           | 0.1              | 0.6              |

MI treatments in 1995 subtracted

-1244 -599 -2367 3.5 1.7 6.6

Unstable angina

639 364 1800 1.8 1.0 5.0

Primary CABG

91317 9 0.20 0.067 0.013 112 40 231

Acute MI treatments in 1995 subtracted

-1244 -599 -2367 3.5 1.7 6.6
Table 1 Estimated deaths prevented or postponed by medical or surgical treatments in Turkey in 2008 (Continued)

| Chronic angina | 3348 | 1105 | 8627 | 9.4 | 3.1 | 24.2 |
|----------------|------|------|------|-----|-----|------|
| CABG surgery 1995-2008 | 103293 | 100 | 0.35 | 0.012 | 0.002 | 632 | 324 | 1093 | 1.8 | 0.9 | 3.1 |
| CABG treatments in 1995 subtracted | 103293 | 100 | 0.00 | 0.022 | 0.000 | 0 | 0 | 0 | 0.0 | 0.0 | -0.1 |
| Angioplasty 1996-2000 | 103293 | 100 | 0.00 | 0.15 | 0.12 | 0.012 | 0.001 | 2840 | 931 | 7066 | 8.0 | 2.6 | 19.8 |
| Aspirin in community | 103293 | 78 | 0.15 | 0.12 | 0.12 | 0.012 | 0.001 | 2840 | 931 | 7066 | 8.0 | 2.6 | 19.8 |
| Statins in community | 103293 | 63 | 0.23 | 0.12 | 0.012 | 0.003 | 2840 | 931 | 7066 | 8.0 | 2.6 | 19.8 |
| Hospital heart failure | 46511 | 43 | 0.20 | 0.166 | 0.033 | 251 | 66 | 744 | 0.7 | 0.2 | 2.1 |
| ACE inhibitor | 46511 | 43 | 0.20 | 0.166 | 0.033 | 251 | 66 | 744 | 0.7 | 0.2 | 2.1 |
| Beta blocker | 46511 | 37 | 0.35 | 0.166 | 0.058 | 378 | 99 | 1121 | 1.1 | 0.3 | 3.1 |
| Spironolactone | 46511 | 40 | 0.30 | 0.166 | 0.051 | 510 | 167 | 1269 | 1.4 | 0.5 | 3.6 |
| Aspirin | 46511 | 68 | 0.15 | 0.166 | 0.025 | 428 | 140 | 1041 | 1.2 | 0.4 | 2.9 |
| Community heart failure | 424611 | 0.085 | 2338 | 747 | 5961 | 6.5 | 2.1 | 16.7 |
| ACE inhibitor | 70 | 0.20 | 0.085 | 0.013 | 479 | 126 | 1430 | 1.3 | 0.4 | 4.0 |
| Beta blocker | 70 | 0.35 | 0.085 | 0.030 | 986 | 323 | 2453 | 2.8 | 0.9 | 6.9 |
| Spironolactone | 25 | 0.31 | 0.085 | 0.030 | 883 | 289 | 2197 | 2.5 | 0.8 | 6.1 |
| Aspirin | 90 | 0.15 | 0.085 | 0.013 | 924 | 303 | 2299 | 2.6 | 0.8 | 6.4 |
| Statins | 40 | 0.00 | 0.085 | 0.000 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 |
| Hypertension treatment | 10029567 | 57 | 0.13 | 0.007 | 0.001 | 2153 | 356 | 4472 | 6.0 | 1.0 | 12.5 |
| Statins for primary prevention | 6133187 | 2 | 0.35 | 0.006 | 0.002 | 41 | 11 | 205 | 0.1 | 0.0 | 0.6 |
| Total treatment | 16671 | 5356 | 35362 | 47.0 | 15.1 | 100.0 |
### Table 2 Deaths from coronary heart disease prevented or postponed as a result of changes in population risk factors in Turkey, 1995-2008

| Risk factor                        | Number of eligible patients | Absolute level of risk factors 1995 | Absolute change | Relative change (%) | Change in risk factors | Beta regression coefficient for change in mortality rate | Deaths prevented or postponed | Relative risk | Number of deaths | Percent of total reduction |
|-----------------------------------|-----------------------------|-------------------------------------|-----------------|---------------------|-----------------------|--------------------------------------------------------|-------------------------------|---------------|------------------|--------------------------|
|                                   |                             | 2008                                |                 |                     |                       |                                                        |                               |               | Best estimate    | Minimum estimate   | Maximum estimate   |
| Smoking prevalence, %             | 27186380                    | 27.0                                | 16.0            | −11.0               | −36.1                 | 2.52                                                   | 9724                         | 7779          | 11669            | 27.2                      | 21.8                        | 32.7                    |
| Men                               | 13497080                    | 44.4                                | 24.6            | −19.8               | −45.5                 | 2.14                                                   | 8377                         | 6702          | 10053            | 48.8                      | 39.0                        | 58.6                    |
| Women                             | 13689300                    | 9.4                                 | 7.2             | −2.2                | −27.2                 | 2.14                                                   | 1347                         | 1077          | 1616             | 7.3                       | 5.8                        | 8.7                     |
| Systolic BP, mmHg                 | 27186380                    | 127.3                               | 124.6           | −2.8                | −2.0                  | 13549                                                  | 8889                         | 18937         | 37.9             | 24.9                      | 53.0                      |
| Men                               | 13497080                    | 124.1                               | 123.3           | −0.7                | −0.0                  | −0.033                                                  | 3579                         | 2318          | 5081             | 15.8                      | 10.3                        | 22.5                    |
| Women                             | 13689300                    | 130.2                               | 125.8           | −4.4                | −3.5                  | −0.041                                                  | 9970                         | 6572          | 13855            | 55.9                      | 36.8                        | 77.6                    |
| Population BP after adjustment for hypertension treatments |                         | 10363                              | 8263            | −2036               | −6.0                  | 10363                                                  | 8263                         | 12990         | 29.0             | 23.1                      | 36.4                      |
| Total cholesterol, mmol/L         | 27186380                    | 4.96                                | 4.97            | 0.01                | 0.01                  |                                                        | −354                         | −226          | −510             | −1.0                      | −0.6                       | −1.4                    |
| Men                               | 13497080                    | 4.91                                | 4.92            | 0.01                | 0.01                  | −0.627                                                  | −200                         | −128          | −288             | −0.0                      | 0.0                        | 0.1                     |
| Women                             | 13689300                    | 5.02                                | 5.03            | 0.01                | 0.01                  | −0.619                                                  | −154                         | −99           | −222             | −0.0                      | 0.0                        | 0.1                     |
| Population TC after adjustment for antilipidemic treatments |                         | −395                                | −237            | −715                | 1.1                    | 0.7                                                    | −3790                        | −2149         | −5784            | 10.6                      | 6.0                        | 16.2                    |
| BMI, kg/m²                        | 27186380                    | 27.4                                | 29.0            | 1.59                | 6.0                   | 0.028                                                   | −3790                        | −2149         | −5784            | 10.6                      | 6.0                        | 16.2                    |
| Men                               | 13497080                    | 26.1                                | 27.9            | 1.80                | 7.0                   | 0.028                                                   | −2117                        | −1202         | −3227            | 12.3                      | 7.0                        | 18.8                    |
| Women                             | 13689300                    | 28.7                                | 30.1            | 1.37                | 5.0                   | 0.028                                                   | −1673                        | −947           | −2557            | 9.0                       | 5.1                        | 13.8                    |
| Diabetes prevalence, %            | 27186380                    | 15.5                                | 18.7            | 3.2                 | 18.7                  | −5086                                                  | −4069                        | −6103         | −14.2            | 11.4                      | 17.1                      |
| Men                               | 13497080                    | 14.5                                | 17.5            | 3.0                 | 20.4                  | 1.93                                                   | −1866                        | −1493         | −2240            | −10.9                      | 8.7                        | 13.0                    |
| Women                             | 13689300                    | 16.4                                | 19.9            | 3.4                 | 17.2                  | 2.59                                                   | −3220                        | −2576         | −3864            | −17.4                      | 13.9                        | 20.8                    |
| Physical inactivity               | 27186380                    | 70.0                                | 65.0            | −5.0                | −7.0                  |                                                        | 1919                         | 1535          | 2303             | 5.4                       | 4.3                        | 6.4                     |
| Mean Fruit & Vegetable consumption in portions | 27186380 | 3.2                                | 3.5             | 32.0                | 10.0                  | 0.041                                                   | 2377                         | 475           | 4974             | 6.7                       | 1.3                        | 13.9                    |
| Total risk factors                | 15112                       | 11597                               | 19333           | 42.3                | 32.5                  | 57.3                                                   |                               |               |                  |                          |                            |                        |

**BMI = weight [kg]/height [m]².**
Population risk factor trend data
For the base year of 1995 were obtained from national representative surveys TEKHARF [9], TURDEP [12] supplemented with regional studies [15,33-35]. For the later years more national surveys became available [15-17]. The main data sources for major risk factors are presented in Additional file 1: Table S2.

The numbers of hospital admissions for CHD
Were estimated using the Ministry of Health (MoH) hospital admission data [36] and from two cohort studies [37,38]. The number of patients undergoing Coronary Artery Bypass Grafting (CABG) and angioplasty were obtained from the MoH hospital admission data supplemented with information by experts from the Turkish Cardiology Association and Cardiovascular Surgery Association, emergency physicians and family physicians. In total 10 experts were initially contacted individually and sent a questionnaire asking their opinions on number of hospital admissions and treatment uptakes for CHD patient groups. Following this they were invited to participate a consensus meeting with other experts. Treatment uptake levels for initial CHD treatments in the hospital were obtained from the hospital survey designed by the research team in the Dokuz Eylul University Hospital and studies published on treatment uptake in the emergency department [39].

The prevalence of angina, post myocardial infarction patients and congestive heart failure in the community was estimated based on representative population surveys including the National Household Survey [3] and Health Surveys 2008 and 2010 [40,41].

Information on treatment uptake in the community was based on PREMISE [27], EUROASPIRE III [26] and population based studies [14,42,43].

The efficacy of specific therapeutic interventions
Was based on recent meta-analyses and randomised controlled trials (Additional file 1: Table S4). The potential effect of multiple treatments in an individual patient was quantified using the Mant and Hicks cumulative relative benefit approach [44] as detailed in Additional file 1.

Change in CHD Deaths between 1995 and 2008
The number of CHD deaths expected in 2008 assuming that mortality rates in 1995 persisted to 2008 was calculated by indirect age standardization. The CHD deaths actually observed in 2008 were then subtracted to quantify the decrease in CHD deaths between 1995 and 2008. These represent the number of deaths prevented or postponed (DPPs) between 1995 and 2008 which the model needs to explain.

The mortality changes attributed to risk factor trends
The DPPs from changes in risk factors were estimated using two approaches: The regression $\beta$ coefficient approach was used to quantify the population mortality impact of change in those specific risk factors, measured as continuous variables, (systolic blood pressure, total cholesterol and BMI). The mortality reduction was then estimated as the product of the CHD deaths observed in 1995 (the baseline year), the subsequent reduction in that risk factor and the regression coefficient that quantified the change in CHD mortality expected per unit of absolute change in the risk factor. The sources of regression were presented in Additional file 1: Table S5.

The second approach, population attributable risk fraction (PAR) was used for categorical variables- smoking, diabetes, physical inactivity and fruit and vegetable consumption using Levin’s equation:

$$\text{PAR} = \frac{\text{Prevalence} \times (\text{Relative Risk} - 1)}{\text{Prevalence} \times (\text{Relative Risk} - 1) + 1}$$

Details of the model methodology have been published previously [7,33] and are illustrated in Additional file 1.

Estimating the contribution of medical and surgical treatments
The model included all medical and surgical treatments in 1995 (the base year) and 2008 (the final year). Treatment uptake data was limited for the year 1995 and thus much of the data included in the model for this year was estimated based on opinion of cardiology experts from Dokuz Eylul University (Additional file 1: Table S2).

The treatment arm of the model consisted of mutually exclusive CHD subgroups: patients hospitalized within the last year for an acute myocardial infarction (AMI), or for unstable angina pectoris or heart failure due to ischemic cardiomyopathy, community-dwelling patients who were post-AMI survivors, patients with chronic angina, patients receiving revascularisation CABG surgery or angioplasty, patients with heart failure in the community and, finally, hypertensive and hypercholesterolemia individuals eligible for primary prevention with lipid lowering therapy.

The mortality reduction for each treatment within each patient group was then calculated as the product of:

The number of patients in that group, their age-specific case fatality, the patient uptake (the proportion receiving that specific treatment) and treatment efficacy (the relative mortality reduction reported in published meta-analyses and trials) Additional file 1.

Case-fatality data were obtained from large, unselected, population-based patient cohorts [45,46]. Survival benefit over a one-year time interval was used for all treatments [47] stratified by age and sex.
Treatment adherence and overlaps
Potential overlaps between different groups of patients were identified and appropriate adjustments were made. Patients group calculations and assumptions are detailed in Additional file 1.

Adherence or the proportion of treated patients actually taking therapeutically effective levels of medication, was assumed to be 100% in hospital patients, 70% in symptomatic community patients, and 50% in asymptomatic community patients based on the available literature [48].

Sensitivity analyses
Because of the uncertainties surrounding many of the values, a multi-way sensitivity analysis was performed using the analysis of extremes method [49]. For each model parameter, a maximum and minimum feasible value was assigned using the 95% confidence intervals from the source documentation when this was available. We otherwise robustly defined these limits as 20% above and below the best estimate (for the number of patients, use of treatment, compliance and case fatality).

Validation: comparison of model estimates with observed mortality falls
The model estimates for the total number of deaths prevented or postponed by each treatment and each risk factor change were summed and compared with the observed changes in mortality for men and women in each age group. Any shortfall in the overall model estimate was then presumed to be attributable either to inaccuracies in our model estimates or to other, unmeasured risk factors [7,24,28]. The study protocol was approved by the Izmir Clinical Research Ethics Committee (Decision no:09-9/15 Date:07.09.2009)

Results
Between 1995 and 2008, age-adjusted CHD mortality rates in Turkey fell 34% in men (from 455.9 to 365.7 per 100 000 aged 35–84 years) and 28% in women (from 378.6 to 324.5 among women aged 35–84 years). In 1995, there were 79,065 deaths among this age group due to CHD. In 2008, a total of 96,365 CHD deaths were recorded representing 35,720 fewer CHD deaths prevented or postponed due to reductions in population mean cholesterol levels, from 127.2 mmHg in 1985 to 124.6 mmHg in 2008, a relative decrease of 2%. After accounting for the 3185 fewer deaths attributable to primary prevention with hypertension (5%) and statins in primary prevention (4%) and heart failure treatments in the hospital (3%) (Table 1).

Major cardiovascular risk factors
Changes in major cardiovascular risk factors together explained approximately 15,110 CHD deaths prevented or postponed (minimum estimate 11595, maximum estimate 19335) (Table 2), representing approximately 42% of the CHD mortality fall between 1995 and 2008. The largest reduction in deaths was explained by substantial reductions in population blood pressure levels, from 127.2 mmHg in 1985 to 124.6 mmHg in 2008, a relative decrease of 2%. After accounting for the 3185 fewer deaths attributable to primary prevention with hypertension treatments, we estimated that approximately 10,365 CHD deaths were prevented or postponed due to reductions in mean blood pressure from life-style and dietary changes from 1995 to 2008, representing some 29% of the overall reduction in CHD mortality (Figure 1, Table 2). Reductions in smoking prevalence in men (~46%) and in women (~27%), also explained approximately 9725 fewer CHD deaths overall.

Population mean cholesterol did not change significantly in Turkey between 1995 and 2008, a 0.02% increase in the population mean cholesterol levels resulted in some 355 deaths. Statin treatments for primary prevention in people with high cholesterol prevented or postponed approximately 725 deaths.

The effects of a decrease in physical inactivity prevalence and increase in fruit and vegetable consumption prevented or postponed approximately 1920 and 2375
deaths representing some 5% and 7% of the total fall in deaths respectively (Table 2).

However, there were adverse trends in diabetes prevalence and BMI levels between 1995 and 2008. Diabetes prevalence increased from 14.5 to 17.5% in men and 16.4% to 19.9% in women (20% and 17% relative increases) from 1995 to 2008, which resulted in approximately 1865 deaths in men and 3220 additional deaths in women representing some 14% of the total deaths. Increases in mean BMI (7.0% in men and 5.0% in women) generated approximately 3790 additional deaths, which effectively represents an additional 10% (minimum 6.0% and maximum 16.2%) to total CHD deaths (Table 2).

**Sensitivity analysis and proportional contributions to the decrease in deaths**

Sensitivity analyses suggested some uncertainty surrounding the risk factor best estimate contribution of 42%, with a range from 33% to 54% (Tables 1 and 2). There was a larger uncertainty in our estimates of the treatment contribution (best estimate 47% - minimum 15%, maximum 99%). However, the proportional contributions of specific treatments and risk factor changes to the overall decrease of CHD mortality in Turkey between 1995 and 2008 remained relatively consistent, irrespective of whether best, minimum or maximum estimates were used (Tables 1 and 2).

**Discussion**

In Turkey, CHD mortality rates fell by 31% between 1995 and 2008 which is similar to the falls reported in affluent Western countries, including England and Wales [7], Ireland [30], Sweden [50] and Italy [51], since the 1980s but occurring later in Turkey.

Approximately 47% of this mortality fall was attributable to the combined effects of modern cardiological treatments and almost 42% was attributable to reduction in major risk factors, particularly smoking and blood pressure. In the previous modelling studies more than half of the fall was explained by risk factor reductions in England and Wales [7], Ireland [30], in Sweden [50], Italy [51]. Modern cardiological treatments together prevented or postponed approximately 16,700 deaths in 2008 in Turkey. Irrespective of whether best, minimum or maximum estimates were used, the most substantial contributions came from secondary prevention and angina treatments.

Revascularisation from CABG surgery and angioplasty together accounted for barely 4% of the total mortality fall, much as in the USA [24] and other countries [7].
This represents a quite small contribution, particularly when considering the large financial and political resources being consumed [52].

Thrombolysis, likewise, only accounted for approximately one fifth of the deaths prevented in the initial treatments for acute myocardial infarction. Aspirin and cardiopulmonary resuscitation contributed far more, similar to other studies [7].

Furthermore, treating angina patients with aspirin in the community prevented almost four times as many deaths as treating unstable angina patients in hospitals, mainly reflecting the far greater numbers of patients eligible for this treatment (Table 1).

Treatment uptake levels were often poor, especially for beta blockers and ACE inhibitors for secondary prevention (Table 1). Earlier work in the UK suggested that if 80% of eligible patients had received appropriate therapy, approximately 30,000 additional deaths might have been prevented or postponed each year in the UK [53]. The same powerful principle would clearly apply in Turkey.

Reductions in the major risk factors between 1995 and 2008 accounted for approximately 15100 fewer deaths in Turkey in 2008. The biggest single contribution, 38%, reflected a 2.74 mmHg absolute decline in systolic blood pressure. The improvements in blood pressure are consistent with improvements in diet rather than treatment. Turkish diet is traditionally rich in fresh fruit and vegetables, legumes and unsaturated fat. Since the socioeconomic improvements in the 1990s, more people are now able to afford fresh fruit and vegetables rather than consuming preserved food that contain substantial salt. However, a recent national survey suggests that daily salt consumptions still very high, approximately 18 gr per day [54]. Traditionally, salt is widely used in pickles, olives, dairy products and bread which together constitute a major part of the Turkish diet. Future population based salt reduction strategies may achieve substantial further blood pressure reductions.

Almost 27% of the mortality fall came from a 41% relative reduction (from 26.5% to 16%) in male smoking. However, smoking prevalence did not change significantly in women. The National Tobacco Control Programme which began in 2008, may further accelerate this decreasing trend in Turkey [55]. The programme aims to increase awareness of the damaging health effects of smoking, together with the government anti-smoking measures including taxation, banning smoking in the public places, intensified anti-smoking campaigns, and the banning of advertising [55].

The adverse trends in obesity and diabetes together contributed over 9000 additional deaths in 2008. This therefore cancelled out much of the benefits attained by the decreases in blood pressure and smoking prevalence during the same period. Obesity and diabetes trends are alarming both in men and women in Turkey [12,13] with major concerns about future continuing deteriorations [56]. New diabetes and obesity control programs were prepared for the period of 2010–2014 [57,58] but these will need to be implemented aggressively to have any benefit.

Population mean cholesterol did not change significantly in Turkey between 1995 and 2008. Stable trends or only small decreases in cholesterol levels were also observed in several other Eastern European countries including Tunisia and Iran [19].

**Modelling strengths and limitations**

Models are potentially useful tools for policy development. They integrate and simultaneously consider huge amounts of data from many different sources. On the other hand, they are very dependent on the quality and extent of data available on CHD risk factor trends and treatment uptakes [59,60].

The data used in the Turkish IMPACT model was generally of good quality. Mortality data was obtained from the Statistical Institute of Turkey (TURKSTAT) which has a long experience of death registry since 1930 [1]. Although the cause of death statistics were based on only urban area and the rates were estimated assuming similar death patterns exist in rural population, our estimates for year 2000 were similar with National Burden of Disease Study. The declining CHD mortality trend starting from the mid 1990s is thought to be real since there were no operational changes in the death reporting system over that time period. Data quality indicators such as the proportion of ill defined codes (symptoms/senility or other heart disease) have remained consistent, which also supports this finding. During the entire period (1995 to 2008) the proportion of senility, symptoms and other heart disease codes were relatively stable in men and women (ranging from 43-53% and 52-63%, respectively) (Data are available upon request from the authors). The demographic information was obtained from the census data that covered whole country, the risk factor trends were obtained from national epidemiological studies. Treatment uptake data was obtained from multicentre national studies (EUROASPIRE III [26], PREMISE [27]) and from a hospital based surveys conducted in recent years [43,61,62]. Certain assumptions were therefore taken to fill in the gaps for missing information including specific patient groups’ data. These assumptions are systematically detailed in the Additional file 1, and were supported by local expert opinions and literature from the region and included in the sensitivity analysis. In the Turkish IMPACT model, we assessed the potential maximum and minimum plausible effects of these factors using rigorous sensitivity analyses which systematically examined the influence
of these uncertainties and the assumptions used in the studies [49].

Our study has several potential limitations. The model included only those adults aged 35 to 64 years, because of very limited data in older age groups. The efficacy data were derived from clinical trials and may have oversimplified effectiveness in usual clinical practice. We considered only deaths from CHD, and ignored “competing causes” such as cancer. However, the reductions in smoking would actually have decreased deaths from lung cancer and some other cancers [63]. Finally, the lag times were not explicitly considered in this model assuming that substantial mortality reduction occurs within 1 to 4 years of quitting smoking or reducing cholesterol [64-66].

This is the first comprehensive modelling study which examines the impact of changes in population risk factors and effective treatments on CHD mortality trends in Turkey. The Ministry of Health developed policy documents and action plans to tackle the growing NCD problem [55,57,58,67]. The Ministry of Health also coordinated the development of national guidelines for CHD, hypertension and diabetes control. This model can be a useful tool to explore potential benefits of implementing certain strategies to prevent the future CHD.

Conclusions
Coronary heart disease mortality in Turkey fell by more than 30 percent between 1995 and 2008. Approximately half of this decline was explained by treatments. However, although changes in major risk factors, mainly smoking and blood pressure potentially explained over half of the decline, much of these benefits were then negated by worry increases in obesity and diabetes. Our findings thus emphasize the role of primary prevention strategies targeting the whole population including healthy diet and tobacco control, plus evidence-based medical treatments for our patients in Turkey.

Additional file

Additional file 1: The Turkish IMPACT Model. Table S1. Main Data Sources Populating the Turkey IMPACT Model. Table S2. Treatment Uptake Data Sources. Table S3. Age-Specific Case Fatality Rates for Each Patient Group. Table S4. Clinical Efficacy of Interventions: Relative Risk Reductions Obtained From Meta-Analyses, and Randomized Controlled Trials. Table S5. Specific Beta Coefficients for Major Risk Factors.

Abbreviations
CHD: Coronary heart disease; NCDs: Non-communicable diseases; TURDEP: Turkish diabetes epidemiology study; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass surgery; ACE-inhibitors: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin-receptor-blockers; ICD: International classification of diseases; MoH: Ministry of health; BMI: Body mass index; AMI: Acute myocardial infarction.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BL conceived the study question, interpreted the findings, and wrote the first draft of the article. KS, GG, HA, DA, HS, SD, YD, ÖA contributed to the data collection and critical appraisal of data sources, analysis and interpretation of findings, and drafting of the manuscript. KB, MÖF, SC and JC contributed to drafting the manuscript, analysis, interpretation of findings, critical revision, and supervision of the study. All authors read and approved the final manuscript.

Acknowledgements
This research received funding from the MRC NPIRI programme, and from European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement no:223075 – the MedCHAMPS project.

References
1. Turkish Statistical Institute (Turkstat) website: Statistics by theme/Population and demographics/vital statistics/statistical tables and dynamic search/death statistics. http://tuikapp.tuik.gov.tr/adnksgatapp/adnkzul.
2. Koc I, Eryurt MA, Adalli T, Seckiner P: Türkiye nin demografik dönüşümü Doguarslan, Alle Planlamanos, Anne-Çocuk Sağlığı ve Beş Yaş Altı Ölümlerik Değişimler: 1968-2008. Ankara: Hacettepe Üniversitesi NÜFUS D鲇lerti Enstitüsü; 2010. http://www.hips.hacetep.edu.tr/Turkey%20Demographics%20%20萦orumu_200410.pdf.
3. Ministry of Health: National Burden of Disease and Cost Effectiveness Study Burden of Disease Final Report, 2004 (in Turkish). Ankara: Refik Saydam Hygiene Center Presidency, 2004. http://ekutuphane.usak.edu.tr/kitaplar/tyurkiye_hastalik_yuku_calismasi.pdf.
4. British Heart Foundation: Coronary Heart Disease Statistics 2010. Oxford, 2010. http://www.bhf.org.uk/publications/view-publication.aspx?id=1001546.
5. Dinc G, Gercelioglu G, Sozmen K, Ang, B, Unal B: Decreasing trends in cardiovascular mortality in Turkey between 1995 and 2008. BMC Public Health 2013, 13:896.
6. Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, LaBarbera DR Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ 2010, 88(2):120–130.
7. Unal B, Critchley J, Capewell S: Explaining the decline in coronary heart disease mortality in England and Wales, 1981–2000. Circulation 2004, 109(1):101–107.
8. Lastikainen T, Critchley J, Varttainen E, Salomaa V, Ketonen M, Capewell S: Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005, 162(8):764–773.
9. Onat A, Senocak MS, Sürdum-Avcı G, Örnek E: Prevalence of coronary heart disease in Turkish adults. Int Cardiol 1993, 39(1):23–31.
10. Altun B, Arici M, Nergizoglu G, Derici U, Karatan O, Turgan C, Sindel S, Erbay B, Hasanoğlu E, Caglar S: Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2002. J Hypertens 2005, 23(10):1817–1823.
11. Arici M, Turgan C, Altun B, Sindel S, Erbay B, Derici U, Karatan O, Erdem Y, Hasanoğlu E, Caglar S: Hypertension incidence in Turkey (the PatentT study) in 2003. J Hypertens 2005, 23(10):1817–1823.
12. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dincagoğlu N, Karabacak G, Kecn S, Telci A, Canbaz B, Turk T, Yilmaz T, Cakir S, Tuomilehto J: Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013. doi:10.1007/s10654-013-9771-5.
14. Ergor G, Soyal A, Sozem K, Unal B, Uçku R, Kılçın B, et al: Balova Heart Study - Rationale and Methodology of the Turkish Cohort. Int J Public Health 2011, 57(3):535–542.

15. Erem C, Hachisaniuoglu A, Deger O, Kosac K, Topbas N, Fanourakis S, Farzadfar F, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Singh GM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, et al: National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377(9765):568–577.

16. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, et al: National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011, 377(9765):578–586.

17. The Ministry of Health of Turkey: Global Adult Tobacco Survey Turkey Report. Ankara, 2010. http://www.havankorcu.org.tr/dosya/Docs_Tutun_Dumaninim__Zarafat/GATS.pdf.

18. Danai G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378(9785):31–40.

19. Finucane MM, Stevens GA, Cowan MJ, Danai G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, et al: National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377(9765):557–567.

20. Capewell S: Explaining the decline in Coronary Heart Disease Mortality in Auckland, New Zealand between 1982 and 1991. Circulation 2000, 102:1511–1516.

21. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Liu JL, Maniadakis N, Gray A, Rayner M: Trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377(9765):568–577.

22. The Ministry of Health of Turkey: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011, 377(9765):578–586.

23. The Ministry of Health of Turkey: Prevalence of diabetes, obesity and hypertension in a Turkish population (Trabzon city). Diabetes Res Clin Pract 2001, 54(2):203–208.

24. The Ministry of Health of Turkey: Prevalence of diabetes, obesity and hypertension in a Turkish population (Trabzon city). Diabetes Res Clin Pract 2001, 54(2):203–208.
59. Critchley JA, Capewell S: Why model coronary heart disease? *Eur Heart J* 2002, 23(2):110–116.
60. Unal B, Capewell S, Critchley JA: Coronary heart disease policy models: a systematic review. *BMC Public Health* 2006, 6:213.
61. Simsek H, Demiral Y, Aslan O, Unal B: Treatment uptake levels in the coronary heart disease patients at hospital discharge. *Int J Cardiol* 2011, 147(1):S56–S516.
62. Sonmez K, Akcay A, Akcakoyun M, Demir D, Eröz O, Onat O, Duran NE, Gencbey M, Degentekin M, Turan F: Distribution of therapeutic procedures and choice of drug therapies in patients with angiographically confirmed coronary artery disease. *Anadolu Kardiyol Derg* 2002, 2(1):18–23.
63. Fichtenberg CM, Glantz SA: Association of the California Tobacco Control Program with Declines in Cigarette Consumption and Mortality from Heart Disease. *N Engl J Med* 2001, 343(24):1772–1777.
64. Critchley J, Capewell S: Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Syst Rev* 2004, 1, CD003041.
65. Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ* 1994, 308(6905):367–372.
66. Capewell S, O’Flaherty M: Mortality falls can rapidly follow population-wide risk factor changes. *Lancet* 2011, 378(9793):752–753.
67. The Ministry of Health of Turkey: Prevention and Control Program for Cardiovascular Diseases: Strategic Plan and Action Plan for the Risk Factors. Ankara, 2009. http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/14.pdf.

doi:10.1186/1471-2458-13-1135
Cite this article as: Unal et al: Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. *BMC Public Health* 2013 13:1135.